参考文献 References
[1] PLUMMER M, DE MARTEL C, VIGNAT J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis [J]. Lancet Glob Health, 2016, 4(9): e609-16
[2] LUZURIAGA K, SULLIVAN J L. Infectious mononucleosis [J]. N Engl J Med, 2010,362(21): 1993-2000.
[3] RICKINSON A B, LONG H M, PALENDIRA U, et al. Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory [J]. Trends Immunol, 2014, 35(4): 159-69.
[4] TAYLOR G S, LONG H M, BROOKS J M, et al. The immunology of Epstein-Barr virus-induced disease [J]. Annu Rev Immunol, 2015, 33: 787-821.
[5] COHEN J I. Epstein-Barr virus infection [J]. N Engl J Med, 2000, 343(7): 481-92.
[6] FUGL A, ANDERSEN C L. Epstein-Barr virus and its association with disease - a review of relevance to general practice [J]. BMC Fam Pract, 2019, 20(1): 62.
[7] WILLIAMS H, CRAWFORD D H. Epstein-Barr virus: the impact of scientific advances on clinical practice [J]. Blood, 2006, 107(3): 862-9.
[8] OKANO M, KAWA K, KIMURA H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection [J]. Am J Hematol, 2005, 80(1): 64-9.
[9] OHSHIMA K, KIMURA H, YOSHINO T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD [J]. Pathol Int, 2008, 58(4): 209-17.
[10] SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J]. Blood, 2016, 127(20): 2375-90.
[11] COHEN J I, JAFFE E S, DALE J K, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States [J]. Blood, 2011, 117(22): 5835-49.
[12] KERR J R. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors [J]. J Clin Pathol, 2019, 72(10): 651-8.
[13] KIMURA H, HOSHINO Y, HARA S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection [J]. J Infect Dis, 2005, 191(4): 531-9.
[14] FISCHER E, DELIBRIAS C, KAZATCHKINE M D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes [J]. J Immunol, 1991, 146(3): 865-9
[15] STINCHCOMBE J C, BOSSI G, BOOTH S, et al. The immunological synapse of CTL contains a secretory domain and membrane bridges [J]. Immunity, 2001, 15(5): 751-61.
[16] TABIASCO J, VERCELLONE A, MEGGETTO F, et al. Acquisition of viral receptor by NK cells through immunological synapse [J]. J Immunol, 2003, 170(12): 5993-8.
[17] ANAGNOSTOPOULOS I, HUMMEL M, KRESCHEL C, et al. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus [J]. Blood, 1995, 85(3): 744-50
[18] ARAI A, YAMAGUCHI T, KOMATSU H, et al. Infectious mononucleosis accompanied by clonal proliferation of EBV-infected cells and infection of CD8-positive cells [J]. Int J Hematol, 2014, 99(5): 671-5.
[19] ARAI A. Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements [J]. Immunol Med, 2018, 41(4): 162-9.
[20] SCOTT L M, GANDHI M K. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies [J]. Blood Rev, 2015, 29(6): 405-15.
[21] ONOZAWA E, SHIBAYAMA H, TAKADA H, et al. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target [J]. Oncotarget, 2018, 9(57): 31077-89.
[22] COHEN J I, NIEMELA J E, STODDARD J L, et al. Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1) [J]. J Clin Immunol, 2015, 35(5): 445-8.
[23] COHEN J I. GATA2 Deficiency and Epstein-Barr Virus Disease [J]. Front Immunol, 2017, 8: 1869.
[24] RODRIGUEZ R, FOURNIER B, CORDEIRO D J, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells [J]. J Exp Med, 2019, 216(12): 2800-18.
[25] KIMURA H, HOSHINO Y, KANEGANE H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection [J]. Blood, 2001, 98(2): 280-6.
[26] ARAI A, IMADOME K I, WATANABE Y, et al. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis [J]. Int J Hematol, 2011, 93(5): 602-9.
[27] 卢根,谢正德,叶玲君,吴润晖,刘春艳,杨双,金颖康,申昆玲. 儿童慢性活动性EB病毒感染的临床特征和危险因素分析[C]//.中华医学会第五次全国儿科中青年学术交流大会论文汇编（上册）.[出版者不详],2008:850-854.
[28] LUO L, WANG H, FAN H, et al. The clinical characteristics and the features of immunophenotype of peripheral lymphocytes of adult onset chronic active Epstein-Barr virus disease at a Tertiary Care Hospital in Beijing [J]. Medicine (Baltimore), 2018, 97(9): e9854.
[29] LIN J, WU H, GU L, et al. Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: A single-center retrospective study in China [J]. Clin Exp Med, 2021, 21(3): 369-77.
[30] KAWAMOTO K, MIYOSHI H, SUZUKI T, et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features [J]. Haematologica, 2018, 103(6): 1018-28.
[31] KIMURA H, KWONG Y L. EBV Viral Loads in Diagnosis, Monitoring, and Response Assessment [J]. Front Oncol, 2019, 9: 62. DOI：10.3389/fonc.2019.00062
[32] FUJII N, TAKENAKA K, HIRAKI A, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection [J]. Bone Marrow Transplant, 2000, 26(7): 805-8.
[33] UEHARA T, NAKASEKO C, HARA S, et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection [J]. Am J Hematol, 2004, 76(4): 368-72.
[34] SATO E, OHGA S, KURODA H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan [J]. Am J Hematol, 2008, 83(9): 721-7.
[35] KAWA K, SAWADA A, SATO M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection [J]. Bone Marrow Transplant, 2011, 46(1): 77-83.
[36] SAWADA A, INOUE M, KAWA K. How we treat chronic active Epstein-Barr virus infection [J]. Int J Hematol, 2017, 105(4): 406-18. DOI：10.1007/s12185-017-2192-6
[37] LUO Y H, YANG J, WEI A, et al. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center [J]. World J Pediatr, 2021, 17(6): 626-36.
[38] COHEN J I. Epstein-barr virus vaccines [J]. Clin Transl Immunology, 2015, 4(1): e32. DOI：10.1038/cti.2014.27
[39] JIN Z, WANG Y, WANG J, et al. Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus [J]. Ann Hematol, 2019, 98(8): 2003-4.
[40] ITO T, KAWAZU H, MURATA T, et al. Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation [J]. Cancer Med, 2014, 3(4): 787-95.
[41] HUE S S, OON M L, WANG S, et al. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach [J]. Pathology, 2020, 52(1): 111-27.
[42] KIMURA H, ITO Y, KAWABE S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmuno- compromised hosts: prospective analysis of 108 cases [J]. Blood, 2012, 119(3): 673-86.
[43] KIMURA H, MORISHIMA T, KANEGANE H, et al. Prognostic factors for chronic active Epstein-Barr virus infection [J]. J Infect Dis, 2003, 187(4): 527-33.
[44] GOTOH K, ITO Y, SHIBATA-WATANABE Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation [J]. Clin Infect Dis, 2008, 46(10): 1525-34.
[45] KAWANO Y, IWATA S, KAWADA J, et al. Plasma viral microRNA profiles reveal potential biomarkers for chronic active Epstein-Barr virus infection [J]. J Infect Dis, 2013, 208(5): 771-9.